

OPPORTUNITIES FOR INDUSTRY COLLABORATION AND SPONSORED RESERACH

We strongly advise that you engage the Office of Biotechnology and Business Development before you submit. This is to ensure that you ONLY disclose NON-CONFIDENTIAL INFORMATION\*, otherwise it might jeopardize future intellectual property (IP) protection. For more information regarding application format, submission, contact Nilam Sinha, Ph.D. (Marketing Manager) at the Office of Biotechnology and Business Development. E-mail: nilam.sinha@einsteinmed.edu; Tel: 718.430.3421

### **Seeking Novel Drugs to Treat Autoimmune Diseases**

Company: Asahi Kasei Pharma

Asahi Kasei, a global pharmaceutical company, is seeking promising novel drugs for the

treatment of a wide range of autoimmune diseases.

Submission deadline: 26th February 2024

 $\rightarrow$  Download PDF

## Innovative Approaches for the Treatment of Nucleotide Repeat Expansion Disorders

Company: AstraZeneca

AstraZeneca is looking to collaboratively uncover and advance groundbreaking approaches for

mitigating nucleotide repeat expansion toxicity. Submission deadline: 6th March 2024

 $\rightarrow$  **Download PDF** 

### Enhancing Targeted Drug Delivery for Diseases Affecting the CNS, Muscle, Heart, and Kidney

Company: AstraZeneca

AstraZeneca is looking to uncover innovative methods for tissue-specific delivery as well as selective tissue-specific expression or regulation that can substantially enhance the therapeutic efficacy and safety profile of their novel molecules.

Submission deadline: 6th March 2024

 $\rightarrow$  Download PDF

#### **Computational Model to Guide Molecular Glue Drug Discovery**

Company: AstraZeneca

AstraZeneca is looking to develop a computational model based on molecular glue ternary binding and kinetics, to guide decision making on project initiation, and key optimization strategies.

Submission deadline: 6th March 2024

→ Download PDF

\*Information is considered NON-CONFIDENTIAL if the information is already in public knowledge, if it is publicly accessible, or if the information was ever publicly disclosed (oral or written) or published (online or printed).

# Office of Biotechnology and Business Development (OBBD)





